CVS Caremark Restores Zepbound Coverage and Adds Foundayo Pill, Erasing Novo's Formulary Advantage

In a major commercial development that fundamentally reshapes the competitive landscape for obesity treatments, pharmacy benefit manager (PBM) CVS Caremark announced on May 28, 2026, that it will end its exclusive preference for Novo Nordisk's Wegovy. CVS Caremark will add Eli Lilly's newly approved oral weight-loss pill, Foundayo™ (orforglipron), to its commercial formularies starting June 1, 2026, and will restore coverage for Lilly's injectable Zepbound® (tirzepatide) as a preferred option starting October 1, 2026.

This decision represents a massive commercial win for Eli Lilly, erasing what had been a critical market-access advantage for Novo Nordisk.

Key Commercial Implications

1. Parity Across the "Big Three" PBMs

With CVS Caremark's policy shift, Eli Lilly's leading obesity therapeutics, Zepbound and Foundayo, are now covered by all three of the largest PBMs in the United States: CVS Caremark, Express Scripts, and OptumRx. This significantly expands the addressable commercial prescription pool for Lilly's assets to millions of additional insured patients.

2. Boosting the Foundayo Oral Launch

While Eli Lilly has captured a dominant share of the injectable obesity market with Zepbound, its newly approved oral small-molecule GLP-1 receptor agonist, Foundayo (approved on April 1, 2026), had experienced a relatively slow start. Early prescription tracking data indicated that Foundayo's adoption pace was only about 30% of the trajectory achieved by Novo Nordisk's competing oral Wegovy pill (approved on December 23, 2025) through its sixth week of launch. Placing Foundayo on CVS Caremark's preferred formulary starting June 1, 2026, is expected to provide a crucial catalyst to accelerate the drug's market penetration.

3. Reversing the 2025 Stock Hit

When CVS Caremark and Novo Nordisk previously struck a deal that granted Wegovy exclusive preferred status on CVS commercial formularies, Eli Lilly's stock faced substantial downward pressure. The reversal of this policy triggered immediate market optimism, with Eli Lilly (NYSE: LLY) shares climbing nearly 6% in early trading following the announcement on May 28, 2026.

Verbatim Quotes and Context

• David Risinger, Analyst at Leerink Partners:

  "Today’s decision reverses that and meaningfully expands the addressable [prescription] pool for Zepbound and Foundayo." — BioPharma Dive

• Tom Scales, Senior Vice President of Market Access at Novo Nordisk:

  "Both versions [of Wegovy] 'have strong formulary access across the U.S. market.'" — BioPharma Dive